EGFR-inhibiting agents such as EGFR tyrosine kinase inhibitors and EGFR-blocking antibodies are approved cancer treatments for a variety of cancers, including non-small-cell lung cancer, pancreatic, breast, and colorectal cancers. Here, EGFR is linked to non-small cell lung carcinoma.